Mental Illness
INVEGA Receives Marketing Authorization In European Union for Treatment of Schizophrenia
Published in Healthcare Finance, Tax and Law Weekly, July 18th, 2007
The European Commission granted marketing authorization for INVEGA(tm) (paliperidone prolonged release tablets), an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA(tm) - through the innovative osmotic delivery system (OROS(R)). In clinical trials, INVEGA(tm) demonstrated significant efficacy as compared to placebo in helping many patients control the symptoms of schizophrenia, and it was generally well tolerated. INVEGA(tm) (paliperidone prolonged release tablets) will be marketed in Europe by Janssen-Cilag. In the U.S., this product is marketed by Janssen,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals Appoints Pharmaceutical and Medical Device Veteran to Board of Directors - Aging
Budget Impasse Requires PA Department of Aging to Furlough Half of its Workforce - Aging
Ed Koch, Bob Weiner Urge Home Care Alternatives to Nursing Homes; Seek Congress Address 'Silent Sadness of Seniors' Forced Unnecessarily to Leave Own Homes - Allscripts
Troy Moritz Joins Allscripts as Chief Security Officer - Alzheimer Disease
Scientists at Chang-Gung University publish new data on Alzheimer disease - Angiology
Judge Grants Diomed Permanent Injunction in '777 Patent Case - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
